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ABSTRACT
Introduction: Osteoarthritis is a chronic 
rheumatoid disease mediated by metallo-
proteinases and inflammatory cytokines. 
Methylsulfonylmethane (MSM) and boswellic 
acids (BA) each show promise in the treatment 
of inflammatory processes, but the efficacy of 
combined treatment with these substances 
in the treatment of arthritis has not yet 
been studied. Methods: In this prospective 
randomized clinical trial, MESACA (for 
“methylsulfonylmethane and boswellic acids 
in the treatment of knee arthritis”), 60 subjects 
affected by arthritis of the knee were randomly 
assigned to an experimental group treated for 
60 days with 5 g of MSM and 7.2 mg of BA daily, 
or a control group which was administered a 
placebo. At 2 and 6 months follow-up (FU), 
the efficacy of combined treatment with these 
two dietary supplements was assessed using the 
visual analog pain scale (VAS) and the Lequesne 
index (LI) for joint function, as well as 
monitoring the use of anti-inflammatory drugs 
(nonsteroidal anti-inflammatory drugs and 
anti-cyclooxygenase-2). Results: Pain, assessed 
with the VAS scale, was worse in the group 
treated with MSM and BA as compared with 
the placebo group at 2 months FU (3.8 vs. 2.7; 
P=0.04), whereas no difference between the 
two groups was observed at 6 months FU 
(2.7 vs. 3.6; P=0.2).  No statistically significant 
differences were found in the LI between the 
two groups at either FU (2 months: 4.8 vs. 
4.2; P=0.51; 6 months: 4.4 vs. 4.5; P=0.91). By 
contrast, a statistically significant difference in 
patients need for anti-inflammatory drugs was 
seen in the experimental as compared to the 
placebo group, even by 2 months FU (0.2 vs. 
0.6 tablets/day; P<0.0001), that persisted up 
to the end of the study (0.1 vs. 0.6 tablets/
day; P<0.0001). Conclusions: Although the 
combined administration of MSM and BA in 
the treatment of gonarthrosis was not shown 
to be more efficacious than placebo in the 
management of the clinical and functional 
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picture, it significantly reduced patients need 
for anti-inflammatory drugs. 
Keywords:  arthrit is ;  boswell ic acids; 
cyclooxygenase-2 inhibitors; Lequesne index 
methylsulfonylmethane; nonsteroidal anti-
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INTRODUCTION
Osteoarthritis (OA) is one of the most common 
forms of degenerative joint disease. It involves 
a degeneration of the joint cartilage structures, 
followed by the development of reactive 
proliferative phenomena at the level of the 
bone and surrounding cartilage.1 From the 
pathophysiological standpoint, it is a complex 
process with multiple etiopathogenesis, caused 
by passive mechanisms of traumatic type, as 
well as active cell-mediated mechanisms that 
induce an anomalous response of the joint 
chondrocytes, leading to an imbalance between 
anabolic and catabolic processes that activates 
inflammatory processes.2 Radiographic signs 
of OA are present in 80% of the population 
>65 years of age, and 60% have symptomatic 
disease.1 The most common sites of localization 
are the knee, hip, spine, interphalangeal 
joints, and trapezo-metacarpal joint. From the 
clinical standpoint, symptomatic OA includes 
pain, stiffness, and functional limitation, that 
progressively worsen and can ultimately lead 
to a total loss of autonomy. This disease has 
high social and health-service costs, that are 
progressively rising, and causes a severe decline 
in the quality of life of affected patients. For 
these reasons it is obvious that all possible 
therapeutic strategies are adopted in patients at 
risk, both for primary prevention and secondary 
treatment.3
The administration of supplements can 
help in the management of the degenerative 
process.4 Treatment of the symptomatic phase 
requires the administration of nonsteroidal 
an t i - in f l ammato r y  d rug s  (NSAIDs ) , 
cyclooxygenase-2 (COX-2) inhibitors, and in 
more severe forms, opioid painkillers.5 These 
drugs are fairly efficacious in reducing the 
pain and inflammation, but it has been amply 
demonstrated that long-term administration is 
associated with a high incidence of side effects.6 
This is why new alternative, safer strategies for 
the management of OA are urgently needed. 
The aim of this work is to verify the clinical 
efficacy, in the treatment of moderate to 
severe gonarthrosis, of the combination of two 
dietary supplements (neutraceuticals), namely 
methylsulfonylmethane (MSM) and boswellic 
acids (BA), that have been shown to have an anti-
inflammatory action in experimental and clinical 
studies,7-9 as well as a good drug safety profile.10-11
MATERIALS AND METHODS
This prospective, randomized, double-
blind placebo controlled trial, MESACA (for 
“methylsulfonylmethane and boswellic acids in 
the treatment of knee arthritis”) was aimed at 
assessing the efficacy and duration of the effects 
of 5 g of MSM and 7.2 mg of BA, administered 
in the commercial formulas Lignisul® and 
Triterpenol® (Laborest Italia S.p.A., Nerviano, 
Milan, Italy), respectively. The study was 
conducted in accordance with the Declaration 
of Helsinki and was approved by the local Ethics 
Committee. Informed consent to take part was 
given by all participants. The knee was the 
chosen anatomical site to assess the efficacy of 
the active ingredients administered. 
Inclusion Criteria 
The inclusion criteria were as follows:
•	 men and women >45 and <85 years of age;
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•	 a diagnosis of OA of the knee according
to the criteria of the American College of 
Rheumatology;12
•	 grade 3 Kellgren and Lawrence radiographic
staging,13 in which the severity of the arthritis 
is assessed on a scale from 0-4, hypothesizing 
a sequential evolution from the manifestation 
of osteophytes through a reduction in the 
width of the joint space, to subchondral 
sclerosis and finally the formation of cysts; 
•	 frequent joint pain (several days a week) for
at least 6 months before recruitment;
•	 pain in the knee, scored at least 2 cm on a
10 centimetric visual analogic scale (VAS), 
where 0 means no pain and 10 is the worst 
pain possible; 
•	 a score of >2 on the Lequesne pain-function
index (LI).14 The LI is a disease-specific 
validated questionnaire that poses a series 
of questions about pain in the knee (five 
questions on a scale from 0 to 2, where 
0 indicates no pain and 2 intense pain), 
functional limitation (four questions, using 
the same scale) and maximum walking 
distance (one question, with a score from 0 
to 6, where 0 indicates the ability to walk for 
an unlimited distance and 6, the inability to 
cover 100 m). The maximim worst final score 
was 24.
Lack of symptoms in other joints was not 
stipulated.
Exclusion Criteria 
The exclusion criteria were as follows:
•	 previous surgery of the affected knee;
•	 disease processes such as rheumatoid arthritis,
autoimmune diseases, systemic diseases, and 
tumors; 
•	 obesity (BMI >30 kg/m2);
•	 altered blood chemistry and kidney, liver,
and metabolic (diabetes mellitus) function; 
•	 intra-articular hyaluronic acid/cortisone
infiltrations to the affected knee within 
3 months before the start of the study;
•	 systemic cortisone treatment taken within
3 months before the start of the study;
•	 supplements (glucosamine, chondroitin
sulfate, bromeline, etc) taken within 
3 months before the start of the study 
(patients were also informed that they were 
not to be taken for the following 6 months).
A 7-day wash-out period for anti-inflammatory 
drugs was stipulated before the first recruitment 
visit. 
Recruitment and Randomization 
The required study population was 60 patients 
affected by gonarthrosis. Patients were 
randomized in a double-blind manner to 
two groups; experimental and control, each 
consisting of 30 patients. To ensure homogeneity, 
the following randomization criteria were 
adopted: sex (female/male), age (45-60 and 
61-85 years old), smoker (yes/no). The clinician 
who conducted the patients recruitment 
and monitoring processes was blinded to 
the treatment administered (experimental or 
placebo), as the randomization was performed 
by a different physician. At recruitment, two 
homogeneous groups (determined by sex, age, 
and smoking habit) were randomly created. 
Study Protocol
The study protocol included a clinical visit, 
medical history, and assessment using the VAS 
and LI at the time of recruitment (T0) and at 
the two follow-up (FU) visits at 2 months (T1) 
and 6 months (T2). If patients were in pain, they 
were allowed to take 500 mg of paracetamol, 
20 mg of pyroxicam, or 50 mg of diclofenac, 
and a period of at least five times the half-life 
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of the drug was allowed to pass before assessing 
symptoms. Patients were asked to write down 
their use of NSAIDs and anti-COX-2 in a diary; 
the mean quantity of anti-inflammatory drug 
tablets/day was evaluated.  
Pharmacological Treatment
All participants were asked to take one drug 
sachet every day for 60 days at the main meal. 
In the experimental group the sachet contained 
5 g of MSM and 7.2 mg of titred BA, and in 
the control group, a placebo. The active 
ingredient has been commercially available 
since 2007 (Artrosulfur®, Laborest Italia 
S.p.A.). The purity of MSM was estimated 
by high resolution gas chromatography to 
be 99.9%.15 The alpha and beta BAs were 
obtained by electromagnetic field extraction, 
resulting in the formation of free-form synergic 
macromolecular triterpene complexes.16
Outcomes Measures
The primary outcome measure was the response 
to treatment, defined as a decrease of pain on the 
VAS and an improvement in the patient’s global 
assessment score on the LI from baseline to the 
2 months FU, and finally the 6 months FU. The 
secondary endpoint was a reduction in patients 
need to take anti-inflammatory drugs.17 All 
analyses were performed at each FU, comparing 
results within each group and between the two 
groups. Because the randomization had taken 
into account only age, sex, and a smoking habit, 
it was hypothesized that at subsequent FUs 
there might be a post-randomization imbalance 
in the clinical evaluations between the two 
groups. We decided to use any difference from 
baseline values in individual parameters, as well 
as absolute values, to compare the experimental 
group with the control group.
Power Analysis and Statistical Analysis
The sample analysis of the study was conducted 
on the primary outcome of the study, ie, the 
pain, expressed as VAS, given the presence 
in literature of several studies on the effects 
of Boswellia serrata and MSM on knee 
arthritis.7,15,18,19 Starting from two homogeneous 
groups determined by the mean value of VAS 
at baseline, we hypothesized a difference of 
two units, with ± standard deviation (SD) of 
two units, in the mean VAS value between 
the two groups, as from the second month of 
therapy. We established a margin of error of 5% 
and confidence intervals (CIs) of 95%; power 
calculation was carried out with the Raosoft 
sample size calculator. This yielded a minimum 
number of subjects per group of 26.
Statistical Analysis
Continuous variables are expressed as means 
and SDs, and categorical variables as proportions 
and 95% CIs. The chi-square test was used to 
compare categorical variables. The means of the 
LI and VAS scores within the two groups were 
compared by student t test for independent 
samples. To compare mean LI and VAS values in 
the two groups at recruitment and FU, student 
t test for paired samples was employed. 
Given the relatively small sample size, we also 
relied on Cohen’s d, a measure of effect size, to 
describe differences between the groups. Cohen’s 
d is defined as the difference between two means 
divided by the pooled SD for those means, and 
is a useful way to conceptualize the magnitude 
of difference between groups when traditional 
parametric testing is not appropriate (eg, because 
of small sample size). Although interpretations 
of Cohen’s d vary, most researchers consider 
0.20-0.40 a small effect, 0.40-0.80 a medium 
effect, and >0.80 a large effect.20
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Significance was set at a value of P<0.05. Stata 
software was used for data processing (Stata 
Corp, College Station, TX, USA).
RESULTS
The enrolled population consisted of 
40 women (66.7%; 95% CI: 54.7-78.6) and 20 
men (33.3%; 95% CI: 21.4-45.3). Mean age 
was 61.8 ± 8.5 years. Each group consisted of 
20 women and 10 men. In the experimental 
group, mean age was 63.4 ± 8.2 years, and in the 
control group 60.2 ± 8.6 years (t=1.45; P=0.51). 
Smokers accounted for 13.3% (n=4; 95% CI: 
1.2-25.2) of the experimental group and 16.7% 
(n=5; 95% CI: 3.3-30) of the control group 
(chi-square = 0.13; P=0.71). At recruitment, 
mean values were 7.2 ± 1.7 on the VAS, and 
11.1 ± 3.7 for the LI. The mean VAS score was 
statistically homogeneous in the experimental 
group (7.5 ± 1.5) versus the control group (6.7 
± 1.9) (t=1.7; P=0.09), but the LI mean values 
were significantly worse in the experimental 
group (12.2 ± 2.7) than the controls (10.1 ± 
4.2) (t=2.29; P=0.03). Daily intake of anti-
inflammatory drugs was comparable in the 
experimental group (0.7 ± 0.4 tablets/day) and 
controls (0.7±0.4 tablets/day ) (t=0.14; P=0.44) 
(Table 1). At FU there was one drop-out in the 
experimental group, for personal reasons not 
imputable to side effects of the treatment. No 
patient reported adverse effects due to daily 
ingestion of the sachet, nor complained of side 
effects.  
Pain Control
In the experimental group, the VAS scores 
reduced significantly from T0 (7.5 ± 1.5) 
to T1 (3.8 ± 1.6) (P<0.0001) and then T2 
(2.7 ± 2.5) (P=0.04). In the control group the 
VAS score was significantly reduced between 
T0 (6.7 ± 1.9) and T1 (2.7 ± 2.4) (P<0.0001), 
but the scores had worsened by T2 (3.6 ± 3.1) 
(P=0.14). Comparison between the VAS scores 
at 2 months showed a statistically significant 
worse mean in the experimental group than the 
controls (t=2.06; P=0.04; d=0.26, small effect 
size). By contrast, at the 6 months FU a better 
mean value was recorded in the experimental 
group, although this was not statistically 
significant (t=–1.2; P=0.2; d=0.33, small effect 
size).
Comparison of the percentage reduction 
in the VAS score was statistically significant in
the control group than the experimental group 
at T1 (d=0.44, medium effect size) (Table 2)
and in the experimental group than the 
controls at T2 (d=0.46, medium effect size) 
(P=0.04) (Table 3).
Table 1. Mean values (± SD) of visual analog scale (VAS), Lequesne index (LI), and anti-inflammatory drug usage in the two 
groups, at recruitment (T0) and the subsequent 2 (T1) and 6 months (T2) follow-up visits.
Group Score T0 T1 T2
Experimental VAS 7.5 ± 1.5 3.8 ± 1.6 2.7 ± 2.5
 LI 12.2 ± 2.7 4.8 ± 3.0 4.4 ± 4.4
 NSAIDs and anti-COX-2 (tablets/day) 0.7 ± 0.4 0.2 ± 0.2 0.1 ± 0.2
Control VAS 6.7 ± 1.9 2.7 ± 2.4 3.6 ± 3.1
 LI 10.1 ± 4.2 4.2 ± 3.6 4.5 ± 4.3
 NSAIDs and anti-COX-2 (tablets/day) 0.7 ± 0.4 0.6 ± 0.4 0.6 ± 0.3
COX-2=cyclooxygenase; NSAID=non-steroidal anti-inflammatory drugs.
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Functional Assessment
It was found that the experimental group had 
a statistically worse LI than the control group 
at baseline (Table 1). In the experimental group, 
the LI showed a significant reduction from T0 
(12.2 ± 2.7) to T1 (4.8 ± 3.0) (P<0.0001). At T2 
there was a trend toward a further improvement 
(4.4 ± 4.4) (P=0.50). In the control group, 
there was a significant improvement from T0 
(10.1 ± 4.2) to T1 (4.2 ± 3.6) (P<0.0001), but a 
decline at T2 (4.5 ± 4.3) (P=0.64). 
No statistically significant difference in 
the mean LI was found either at 2 months 
(t=0.66; P=0.51; d=0.19, negligible effect size) 
or 6 months FU (t=–0.1; P=0.91; d=0.27, small 
effect size) between the experimental group and 
the control group. 
Comparison of the percentage reduction of 
the LI in the two groups was not statistically 
significant either at T1 (d=0.19, negligible size 
effect) (Table 4) or T2 (d=0.10, negligible size 
effect) (P>0.05) (Table 5).
Use of Anti-Inflammatory Drugs 
In the experimental group, the use of anti-
inflammatory drugs reduced significantly 
from T0 (0.7 ± 0.4 tablets/day) to T1 
(0.2 ± 0.2 tablets/day) (t=7.76; P=0.0001) and 
then T2 (0.1 ± 0.2 tablets/day) (T1 vs. T2: 
t=2.05; P=0.02; T0 vs. T2: t=7.46; P<0.0001). In 
the control group, no statistically significant 
variation in anti- inflammatory drugs
dosage was recorded from T0 (0.7 ± 0.4 tablets/
day) to T1 (0.6 ± 0.4 tablets/day) (t=1.57; 
P=0.06), and T2 (0.6 ± 0.3 tables/day) (T1 vs. 
T2: t=0.65; P=0.25; T0 vs. T2: t=1.74; P=0.04) 
(Table 1).
Comparison of the use of anti-inflammatory 
drugs in the two groups showed that at 2 months 
FU this parameter had a statistically significant 
lower value in the experimental group than in 
the control group (t=4.88, P<0.0001; d=1.28, 
large effect size). This statistically significant 
improvement persisted at the 6 month FU 
(t=7.03, P<0.0001; d=1.84, large effect size).
Table 2. Mean values (± SD ) of reduction (expressed as 
a percentage) of visual analog scale (VAS) at 2 months 
follow-up (T1) and statistical comparison between the 
two groups.
Group VAS reduction (%) at T1 t P
Experimental 49.5 ± 19.1 
–1.67 0.04
Control 61.5 ± 34.2  
Table 5. Mean values (± SD) of reduction (expressed as 
a percentage) of Lequesne index (LI) at 6 months 
follow-up (T2) and statistical comparison between the 
two groups.
Group LI reduction (%) at T2 t P
Experimental 64.7 ± 33.2 
–0.39 0.34
Control 61.2 ± 34.2  
Table 3. Mean values (± SD) of reduction (expressed as 
a percentage) of visual analog scale (VAS) at 6 months 
follow-up (T2) and statistical comparison between the 
two groups.
Group VAS reduction (%) at T2 t P
Experimental 62.6 ± 33.9 
1.76 0.04
Control 42.1 ± 53.7  
Table 4. Mean values (± SD) of reduction (expressed as 
a percentage) of Lequesne index (LI) at 2 months 
follow-up (T1) and statistical comparison between the 
two groups.
Group LI reduction (%) at T1 t P
Experimental 60.6 ± 22.4 
–0.70 0.24
Control 64.9 ± 25.6  
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Size Effect
Estimating effect size using Cohen’s d to 
compare the two groups in relation to the 
primary outcome resulted in similar values 
at 2 months FU for the VAS and at 6 months 
FU for both VAS and LI (small effect size). No 
significant difference was found for LI at the first 
FU (negligible effect size). When considering the 
percent reduction, we found better VAS scores 
in the experimental group than in controls at 
T1 and T2 (medium effect size), whereas no 
differences emerged between the two groups for 
LI at either FU (negligible effect size).
Estimating effect size in relation to the use of 
anti-inflammatory drugs resulted in important 
differences between the two study groups at the 
2 months and 6 months FU (large effect size).
DISCUSSION 
In recent years, many experimental and clinical 
studies have addressed the etiopathogenesis of 
OA and evaluated new therapeutic strategies 
for improving the management of the disease. 
The pathogenic mechanism underlying arthritic 
processes is complex: an initial lesion of the 
cartilage stimulates the mechanotransducers 
responsible for activating metalloproteinases 
(MMP) and local pro-inflammatory cytokines 
(CK) that trigger a cartilage degeneration
process. This is then maintained by an increased 
cell expression of the corresponding membrane 
receptors and a local increase in inflammatory 
cells.2
Therapeutic guidelines for OA of the knee 
have been drawn up by various study groups, 
mainly the Osteoarthritis Research Society 
International (OARSI)20 and the European League 
Against Rheumatism (EULAR).21 Aims include 
education of the patient about the pathogenesis 
and management of OA, pain relief, functional 
improvement and a reduction of disability, 
disease prevention, and slowing of the disease 
process and its consequences. The different 
therapies for OA have been evaluated and 
evidence-based conclusions drawn. Regulating 
agencies such as the European Medicines 
Agency (EMA) and the US Food and Drug 
Administration (FDA) have warned that caution 
should be used when prescribing NSAIDs and 
COX-2 inhibitors,22 because these drugs can 
have serious side effects on the gastroenteric 
tract, the kidney, the cardiovascular system, the 
liver, and the hemostatic and immune systems, 
and allergic reactions have also been reported.6 
In addition, possible interactions must be 
taken into account between anti-inflammatory 
agents and other drugs that the patient may 
need to take for concomitant diseases such 
as corticosteroids, heparin, aminoglycosides, 
diuretics, angiotensin-converting enzyme (ACE) 
inhibitors, beta-blockers, digoxin, cisplatin, 
methotrexate, and oral anticoagulants. Neither 
the guidelines nor the regulating agencies 
indicate any drugs that are able to modify the 
degeneration of the joint structure and disease 
course. However, the EULAR guidelines stress 
that according to randomized studies, the 
strongest evidence of a beneficial effect on the 
symptoms of gonarthrosis has been obtained 
with the use of glucosamine sulfate.23 In recent 
years, viscosupplementation with hyaluronic 
acid has yielded good results in research on 
efficacious strategies to improve pain control 
and joint mobility.24 One or more treatment 
cycles can achieve pain relief and improved joint 
function lasting several months.25 However, 
possible side effects, such as the risk of local 
infections, have been described, as well as a new 
acute onset of pain.26
The rationale for administering MSM 
and BA in arthritic patients was drawn 
from experimental studies showing that 
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neutraceuticals can modulate the pathogenic 
mechanisms underlying OA at several levels.7-9 
MSM is a sulfuric organic compound composed 
of 34% sulfur, due to the oxidation of dimethyl 
sulfoxide. Coffee, milk, meat, eggs, fish, 
wheat, leafy plants, and vegetables have a rich 
content of MSM and can restore the integrity 
of connective tissue, due to the sulfur content.27 
Experimental studies have demonstrated 
actions inhibiting various CKs involved in
inflammatory processes.7 Apart from these anti-
inflammatory effects, MSM has been reported 
to have chemopreventive effects, inhibiting 
prostacyclin (PGI) synthesis, as well as an anti-
sclerosis action, activating the metabolism of the 
eicosanoids and scavenging free radicals.28 No 
side effects have been described even at doses of 
5 to 7 times the maximum recommended dose.10
Clinical applications of MSM in the treatment 
of hyperacidity, parassitosis, constipation, 
skeletal-muscle pain, arthritis, allergies, and 
immunomodulation have yielded promising 
results.8 Many clinical studies support the 
efficacy of dietary supplements with MSM 
in patients with joint diseases such as OA, 
rheumatoid arthritis (RA) and lupus. In OA 
patients, the use of MSM in association with 
other supplements, such as glucosamine and 
chondroitin sulfate, has been shown to reduce 
pain and swelling and improve joint mobility 
and function.29-31 Other authors conducting 
clinical studies to evaluate applications in the 
treatment of gonarthrosis have shown that MSM 
administered for 12 weeks alone or in association 
with glucosamine has effects on reducing pain 
and improving joint function that persist for 
12 weeks after the end of treatment.9 Apart 
from the above-described systemic applications, 
the efficacy of sulfur in the local treatment of 
arthrtitic disease has been amply described 
in experiences of bathing patients in mineral 
sulfate-bicarbonate-calcium water.32
The pharmacological and clinical properties 
of Boswellia extract have recently undergone 
a systematic study.11 The main active 
pharmacological ingredients are alpha and beta 
BAs, that inhibit inflammatory processes, acting 
on cyclo- and lipo-oxygenases to produce a good 
anti-inflammatory and analgesic action, and 
reducing glycosaminoglycan (GAG) degradation 
of the joint cartilage.33 The incidence of side 
effects, such as diarrhea, abdominal pain, 
and nausea, reported in some studies, did not 
seem to show appreciable differences between 
the treatment group and placebo controls.11
In the rat, the absence of teratogenic effects 
has been ascertained.33 Promising results have 
been obtained in clinical applications to treat 
asthma, RA, Crohn’s disease, collagenous 
colitis, and arthritis.11 Kimmatkar et al.34 and 
Sontakke et al.35 reported that in patients 
affected by gonarthrosis, the administration of 
Boswellia serrata extract for a period of between 
6 weeks and 6 months improves the clinical and 
functional picture, and the results were stable 
1 month after treatment. 
The use of anti-inflammatory and analgesic 
drugs and bone mineral supplements is supported 
in literature, as well as physiokinesitherapy 
applications, to manage initial forms of arthritis 
and induce regression in symptomatic phases.4
A clinical study reported the efficacy of 
the combined administration of the these 
two dietary supplements in the treatment 
of degenerative joint disease, studying 
patients affected by dysfunctions of the 
temporomandibular joint. The efficacy of the 
supplements was assessed on pain management, 
improvements in the maximum mandibular 
range of movement, and magnetic resonance 
imaging (MRI) staging.15 The treatment was 
shown to improve pain and joint function after 
24 weeks, but no significant differences were 
found, as compared to the control group. The 
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comparable results were attributed to the use 
of NSAIDs. However, significant differences 
emerged in the treated group at mandibular 
MRI: in 12 of the 26 patients treated, there was 
an improvement in the structure of the inter-
articular disk and reduced joint degeneration. 
These findings support the hypothesis that 
MSM and BA, by limiting the formation of free 
radicals and blocking leukotriene synthesis, may 
inhibit the inflammatory processes mediated by 
inflammatory CKs and MMP underlying the
joint denegeration process.7,8,31,34,36 It may be 
that they have an action stimulating cartilage 
formation, that could explain the improvements 
observed in the experimental group. Further 
studies are needed to examine their effects 
on different joint structures and in different 
diseases. 
In view of the above-described experimental 
and clinical evidence, this first prospective 
randomized double-blind clinical trial was 
designed to evaluate the efficacy of combined 
treatment with MSM and BA in patients affected 
by gonarthrosis. Improvements of the clinical 
and functional picture were assessed by the VAS, 
to measure pain, and the LI, to quantify the 
severity of the functional limitation. Particular 
care was taken to monitor the use of anti-
inflammatory drugs, bearing in mind the side 
effects of these drugs when taken for prolonged 
periods in chronic diseases like arthritis.37 The 
primary endpoint of this study was to assess the 
efficacy of the treatment in terms of reducing 
pain and improving joint function. At the 
2 month FU, a trend toward an improvement 
was observed in both groups. The fact that there 
seemed to be an improvement in symptoms 
also in the placebo group comes as no surprise 
in a prospective clinical study, in which one of 
the important problems is to prevent patient 
drop-out, since it involves a number of different 
clinical examinations and assessments.38 In this 
study, patients were asked to note down their 
need to take anti-inflammatory drugs in a diary. 
In any case, the initial improvement in the VAS 
score and LI recorded in the placebo group was 
no longer present by the 6 months FU, whereas 
the experimental group showed a trend toward 
a further improvement by the end of the study, 
although this was not significant.  
Comparison of the effect of the therapy 
between the two groups demonstrated that 
the mean VAS score was statistically worse in 
the experimental group at the 2 month FU, 
whereas there were no significant differences 
regarding the VAS score at 6 months, and the 
LI at both 2 and 6 months.  Analysis of the 
primary outcome measure did not therefore 
reveal a greater efficacy of the two supplements. 
The discordance between the clinical results 
obtained in this study and the improved 
results reported in literature may be correlated 
to patients more severe disease within the 
study (moderate-severe grade of Kellgren and
Lawrence radiographic staging13) as compared 
to the patients recruited in previous studies 
(mild-moderate grade).15,30
The clinical effect of therapy with MSM and 
BA was assessed by considering the minimal 
clinically-important difference (MCID); that 
is, the smallest difference in an outcome score 
which a patient perceives as beneficial.39 For 
knee OA Tubach et al.40 defined it as −1.99 cm on 
the VAS. At the end of our study the difference 
for the VAS between the experimental group 
and control group was 3.6 cm versus 2.7 cm, ie, 
a difference of only –0.9 cm, and therefore not 
clinically significant in the light of the MCID. 
Also, in terms of effect size, the patients treated 
with MSM and BA showed similar symptoms to 
those of the placebo group (small effect size).
For the LI, no MCID reference value was 
found in the literature to help compare the 
groups; in any case, estimates of effect size 
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suggest that the functional picture was similar 
in both groups at the end of the study (small 
effect size).
These results call into question the need 
to analyze the second study endpoint; in 
other words, the patients need to take anti-
inflammatory drugs. To monitor this use, 
patients were instructed to take these drugs in 
case of need, noting this down in a diary. Of 
note, there was a statistically and clinically 
significant difference in the need to take NSAIDs 
and anti-COX-2 between the patients in the 
experimental group and the controls, with a 
large size effect. 
On this basis, we may hypothesize that 
the trend toward a clinical improvement 
may be justified, in the placebo group, by 
the continued administration of NSAIDs and 
anti-COX-2, and in the experimental group, 
by the administration of MSM and BA. This 
supports the hypothesis that the combined 
administration of these two supplements can 
assist in the management of the clinical and 
functional symptoms of the patient with 
gonarthrosis in substitution of the use of anti-
inflammatory drugs. Estimating effect size in 
relation to the use of anti-inflammatory drugs 
confirms a significant reduction in the use of 
NSAIDs and anti-COX-2 in the experimental 
group.  
Thus, although the primary endpoint 
was not satisfied, further studies with a 
longer lasting, different design, and of larger 
populations, are needed to establish whether 
the administration of MSM and BA can 
replace that of NSAIDs and anti-COX-2 in the 
management of the OA patient. In fact, despite 
the similar clinical-functional picture in the two 
groups, as emerged by valuation of the MCID 
and by calculation of the size effect, the use 
of anti-inflammatory drugs was significantly 
different. The two supplements were shown 
to induce a significantly reduced need for 
anti-inflammatory drugs even after 2 months, 
and this effect still persisted at 4 months after 
suspension of the dietary supplementation. A 
trial specifically designed to directly compare 
MSM and BA with NSAIDs would be needed in 
order to assess whether they could be regarded 
as the preferred medication in OA. 
A strong point of this work is the longer 
period of verification of the effects of MSM 
than has previously been described; up to 4 
months after the end of treatment. Kim et al.30
monitored the beneficial effects induced by 
MSM during 12 weeks’ administration, while 
Usha and Naidu19 reported the persistence of 
MSM effects at FU, 12 weeks after the end of 
treatment. We hypothesized that administration 
of BA could contribute to a longer duration in 
the combined supplement administrated in this 
study, since the effects of these acids have been 
shown to be long-lasting. In fact, although 
Sengupta et al.36 monitored improvements 
only during the 90 days of administration of 
BA, Sontakke et al.35 described stable effects at 
6 months after the end of treatment. 
Limitations of this study include the absence 
of a control group treated with supplements 
and the small study population, which could 
explain the statistically significant differences 
in the LI at baseline between the two groups. 
It is important to note that patients need to 
be constant and collaborative, and take the 
dietary supplement daily for a long period of 
time, although in this study the treatment 
was well tolerated and compliance was high 
(29/30 patients in the experimental group), 
with no side effects being reported. Besides, 
the present trial explored effects on patients 
with gonarthrosis using clinical and functional 
scales but not imaging tests, since previous 
experiences with bone mineral supplements 
did not reveal visible tissue modulation at such 
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tests.34 In view of the findings of Castroflorio et 
al.,15 it would now be interesting to explore the 
effects of MSM and BA at the cartilage level by 
imaging tests. Although the use of a low LI (>2) 
in the inclusion criteria could be considered 
another weak point of our study, resulting in 
the recruitment of asymptomatic patients or 
those with only minor functional symptoms, 
the low percentage (<10%) of patients with a 
low LI allows the study to exclude the presence 
of a floor effect in the patient population. 
CONCLUSION
Given the putative mechanisms of action, 
the use of MSM and BA could be supported 
in the treatment of OA. Evidence of efficacy 
when administered singly has been reported, 
but this is the first study to assess the efficacy 
of combined treatment of MSM and BA in 
the management of gonarthrosis. Although 
these results did not reveal a greater efficacy 
than the placebo, it was found that they 
significantly reduced patients need to take anti-
inflammatory drugs. Further studies are needed 
to investigate this potential effect. 
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